The Relationship Between the Differential Expression of FosB Protein in Laryngeal Cancer Tissues and Clinical Prognosis

NCT06836765 | Not Yet Recruiting

• 1 other identifier: NeijiangPH2
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods. If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues

Conditions

Laryngeal Carcinoma

Keywords

Laryngeal cancer; FosB(FBJ murine osteosarcoma viral oncogene homolog B) gene; Immunohistochemistry; Cox regression analysis

Outcome Measures

Primary Outcomes (1)

• the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined.

  the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined by immunohistochemical test of pathological sections.

  one month

Secondary Outcomes (1)

• _Experimental result of western blot and PCR._Correlation analysis data between clinical information and experimental results..

  three months

Study Arms (2)

The expression of FosB positive group

Researcher will incorporate the positive expression of FosB protein in laryngeal cancer tissues into the positive study group by immunohistochemical methods!

Other: the expression positive in laryngeal cancer tissue

The expression of FosB negative group

Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!

Other: the expression negative in laryngeal cancer tissue

Interventions

the expression negative in laryngeal cancer tissue OTHER

Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!

The expression of FosB negative group

the expression positive in laryngeal cancer tissue OTHER

Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!

The expression of FosB positive group

Eligibility Criteria

• Age: 35 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Researchers are Collecting 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in research institution.

You may qualify if:

• laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;
• Primary tumor of Laryngeal ,and there was no distant metastasis;
• Standard treatment such as surgery and Preliminarily-diagnosed parients;
• full clinical and pathological data information and good follow-up;
• there was no previous fatal diseases such as complicated tumors.

You may not qualify if:

• Secondary cancer or cancer with distant metastasis;
• Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
• Clinical and pathological data were missing and loss to follow-up;
• Patients who abandoned treatment or standard treatment procedures has not been completed;
• The past medical history of other lethal diseases such as complicated tumors.

Sponsors & Collaborators

• Yang ji: lead

Study Sites (1)

Cllinical Laboratory of Chuanbei Medical College

Nanchong, China/SiChuan, 637000, China

Location

Related Publications (3)

• Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 Nov;3(11):859-68. doi: 10.1038/nrc1209. No abstract available.

  PMID: 14668816 BACKGROUND

• Liu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018 Jun 11;26(5):683-690. doi: 10.3727/096504017X14982585511252. Epub 2017 Jun 24.

  PMID: 28653602 BACKGROUND

• Hung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017 May;41(5):596-606. doi: 10.1097/PAS.0000000000000795.

  PMID: 28009608 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

the investigators shall are Collecting 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in our institution. In order to make pathological sections,the investigators will are Collect their laryngeal cancer pathological tissues and adjacent tissues of these paitents.

MeSH Terms

Conditions

Laryngeal Neoplasms

Condition Hierarchy (Ancestors)

Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Laryngeal Diseases; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Otorhinolaryngologic Diseases

Central Study Contacts

Yang Ji

CONTACT

+86 18283201832; 450638020@qq.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: associate professor

Study Record Dates

• First Submitted: August 17, 2024
• First Posted: February 20, 2025
• Study Start: April 1, 2025
• Primary Completion: April 1, 2025
• Study Completion: May 1, 2025
• Last Updated: February 20, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)